101
|
Rand AJ, Flejter WL, Dowling CA, Brooke LM, Boland GM, Kroshinsky D, Rosenblum IR, Hernandez-Perez M, Reimann JDR. Atypical ALK-positive Spitz tumors with 9p21 homozygous deletion: Report of two cases and review of the literature. J Cutan Pathol 2017; 45:136-140. [DOI: 10.1111/cup.13057] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2017] [Revised: 10/08/2017] [Accepted: 10/10/2017] [Indexed: 02/03/2023]
Affiliation(s)
- Andrew J. Rand
- Miraca Life Sciences; Newton Massachusetts
- Department of Dermatology; Tufts Medical Center; Boston Massachusetts
| | | | - Christopher A. Dowling
- Miraca Life Sciences; Newton Massachusetts
- Department of Dermatology; Tufts Medical Center; Boston Massachusetts
| | | | | | - Daniela Kroshinsky
- Department of Dermatology; Massachusetts General Hospital; Boston Massachusetts
| | | | - Marier Hernandez-Perez
- Miraca Life Sciences; Newton Massachusetts
- Department of Dermatology; Tufts Medical Center; Boston Massachusetts
| | - Julie D. R. Reimann
- Miraca Life Sciences; Newton Massachusetts
- Department of Dermatology; Tufts Medical Center; Boston Massachusetts
| |
Collapse
|
102
|
Testa U, Castelli G, Pelosi E. Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells. Med Sci (Basel) 2017; 5:E28. [PMID: 29156643 PMCID: PMC5753657 DOI: 10.3390/medsci5040028] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2017] [Revised: 10/31/2017] [Accepted: 11/08/2017] [Indexed: 12/11/2022] Open
Abstract
Melanoma is an aggressive neoplasia issued from the malignant transformation of melanocytes, the pigment-generating cells of the skin. It is responsible for about 75% of deaths due to skin cancers. Melanoma is a phenotypically and molecularly heterogeneous disease: cutaneous, uveal, acral, and mucosal melanomas have different clinical courses, are associated with different mutational profiles, and possess distinct risk factors. The discovery of the molecular abnormalities underlying melanomas has led to the promising improvement of therapy, and further progress is expected in the near future. The study of melanoma precursor lesions has led to the suggestion that the pathway of tumor evolution implies the progression from benign naevi, to dysplastic naevi, to melanoma in situ and then to invasive and metastatic melanoma. The gene alterations characterizing melanomas tend to accumulate in these precursor lesions in a sequential order. Studies carried out in recent years have, in part, elucidated the great tumorigenic potential of melanoma tumor cells. These findings have led to speculation that the cancer stem cell model cannot be applied to melanoma because, in this malignancy, tumor cells possess an intrinsic plasticity, conferring the capacity to initiate and maintain the neoplastic process to phenotypically different tumor cells.
Collapse
Affiliation(s)
- Ugo Testa
- Department of Oncology, Istituto Superiore di Sanità, 00161 Rome, Italy.
| | - Germana Castelli
- Department of Oncology, Istituto Superiore di Sanità, 00161 Rome, Italy.
| | - Elvira Pelosi
- Department of Oncology, Istituto Superiore di Sanità, 00161 Rome, Italy.
| |
Collapse
|
103
|
Tetzlaff MT, Reuben A, Billings SD, Prieto VG, Curry JL. Toward a Molecular-Genetic Classification of Spitzoid Neoplasms. Clin Lab Med 2017; 37:431-448. [DOI: 10.1016/j.cll.2017.05.003] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
104
|
Somatic mutation analysis in melanoma using targeted next generation sequencing. Exp Mol Pathol 2017; 103:172-177. [PMID: 28822769 DOI: 10.1016/j.yexmp.2017.08.006] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2017] [Accepted: 08/15/2017] [Indexed: 01/22/2023]
Abstract
Advanced stage malignant melanoma often responds poorly to therapy with low survival rates. New therapeutic approaches are based upon a growing understanding of the underlying molecular abnormalities. We demonstrate the feasibility of a next generation sequencing (NGS) assay, which targets hotspots in 50 cancer genes, to assess genotypes that may influence therapeutic selection and response. DNA was extracted from formalin fixed paraffin embedded (FFPE) melanoma specimens to create multiplexed libraries which were sequenced. Of the 121 cases, BRAF mutations were present in 48 cases (40%) and NRAS mutations in 24 cases (20%). We identified other gene variants in 20 BRAF-mutated cases. Additional gene variants were also identified in the 57 BRAF wild-type cases. Four patients harbored different gene mutations at metastatic sites as compared to their primary lesions or metastasis from different sites. Concurrent gene variants may provide additional targets for future therapies and may suggest alternative mechanisms of secondary resistance.
Collapse
|
105
|
Abstract
Spitz tumors are melanocytic neoplasms hallmarked by large cell size, lack of high-grade atypia, and a regular architecture. Most are nonpigmented or poorly pigmented. Malignant potential ranges from absent (Spitz nevus), to fully present (spitzoid melanoma), with a further, ill-defined group of Spitz tumors with limited metastatic potential. Microscopic evaluation may prove inconclusive in some instances, resulting in a verdict of Spitz tumor of uncertain malignant potential (STUMP). STUMP is, therefore, not an entity, and should not be equated with Spitz tumors with limited metastatic potential. Novel diagnostic techniques are yielding promising results, and further evaluation is ongoing.
Collapse
Affiliation(s)
- F D Menezes
- Department of Pathology, Instituto Portugues de Oncologia do Porto FG, Rua Dr Antonio Bernardino de Almeida, Porto 4200-072, Portugal
| | - W J Mooi
- Department of Pathology, VU University Medical Center, PO Box 7057, Amsterdam 1007 MB, The Netherlands.
| |
Collapse
|
106
|
Genomic Assessment of Blitz Nevi Suggests Classification as a Subset of Blue Nevus Rather Than Spitz Nevus: Clinical, Histopathologic, and Molecular Analysis of 18 Cases. Am J Dermatopathol 2017; 40:118-124. [PMID: 28475519 DOI: 10.1097/dad.0000000000000918] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Blitz nevi/tumors are a distinct subset of melanocytic neoplasia which show mixed morphologic features of Spitz and blue nevus. Genomically, most blue nevi have GNAQ or GNA11 mutations while most Spitzoid neoplasms have either an HRAS mutation or translocations involving MET, ROS, BRAF, ALK1, NTRK1, and RET. The criteria used for the assessment of malignancy in blue and Spitzoid lesions are different, and these lesions have different prognostic markers. In this study, we assess the clinical, morphological, and genomic changes in 18 cases of Blitz nevi/tumors to better characterize this subset of neoplasms and determine their optimal genomic classification. Most lesions occurred on the extremities followed by the head and neck region typical of blue nevi. Histology showed most cases having a prominent plexiform growth pattern with cells aggregating around the adnexal structures and neurovascular bundles also typical of blue nevi. Using next generation sequencing, we detected the presence of somatic mutations in GNAQ or GNA11 in 4 of 7 cases (57%) of Blitz nevi with sufficient DNA available for sequencing. Normal skin samples in these 4 cases were sequenced to confirm that the GNAQ or GNA11 mutations were somatic mutations. All 4 cases were negative for immunohistochemical assessment for wild-type BRAF, RET, ALK, and NTRK1 and mutational analysis of HRAS was also negative in all cases. Hence, our study suggests that Blitz nevi/tumors are a distinct subset which genomically are best classified as a subset of blue nevi.
Collapse
|
107
|
Urso C. Diagnostic problems in spitzoid neoplasms. Pathology 2017; 49:325-326. [DOI: 10.1016/j.pathol.2016.11.018] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2016] [Accepted: 11/27/2016] [Indexed: 11/15/2022]
|
108
|
Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors. Neoplasia 2017; 19:196-206. [PMID: 28161563 PMCID: PMC5293722 DOI: 10.1016/j.neo.2017.01.003] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2016] [Revised: 01/18/2017] [Accepted: 01/18/2017] [Indexed: 02/07/2023] Open
Abstract
Companion diagnostics rely on genomic testing of molecular alterations to enable effective cancer treatment. Here we report the clinical application and validation of the Oncomine Focus Assay (OFA), an integrated, commercially available next-generation sequencing (NGS) assay for the rapid and simultaneous detection of single nucleotide variants, short insertions and deletions, copy number variations, and gene rearrangements in 52 cancer genes with therapeutic relevance. Two independent patient cohorts were investigated to define the workflow, turnaround times, feasibility, and reliability of OFA targeted sequencing in clinical application and using archival material. Cohort I consisted of 59 diagnostic clinical samples from the daily routine submitted for molecular testing over a 4-month time period. Cohort II consisted of 39 archival melanoma samples that were up to 15years old. Libraries were prepared from isolated nucleic acids and sequenced on the Ion Torrent PGM sequencer. Sequencing datasets were analyzed using the Ion Reporter software. Genomic alterations were identified and validated by orthogonal conventional assays including pyrosequencing and immunohistochemistry. Sequencing results of both cohorts, including archival formalin-fixed, paraffin-embedded material stored up to 15years, were consistent with published variant frequencies. A concordance of 100% between established assays and OFA targeted NGS was observed. The OFA workflow enabled a turnaround of 3½ days. Taken together, OFA was found to be a convenient tool for fast, reliable, broadly applicable and cost-effective targeted NGS of tumor samples in routine diagnostics. Thus, OFA has strong potential to become an important asset for precision oncology.
Collapse
|
109
|
A review of kinase fusions in melanocytic tumors. J Transl Med 2017; 97:158-165. [PMID: 27892929 DOI: 10.1038/labinvest.2016.122] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2016] [Revised: 10/03/2016] [Accepted: 10/23/2016] [Indexed: 01/03/2023] Open
Abstract
Translocations resulting in a kinase fusion are well reported in many tumor types and indeed can be defining, particularly in the case of hematopoietic malignancies. The recent reports of multiple protein kinase fusions within melanocytic neoplasms, particularly in those with spitzoid morphology, have heralded a new era of classification of these melanocytic tumors. Seen within approximately half of all spitzoid neoplasms and present within the full spectrum of benign, atypical, and malignant lesions, kinase fusions likely represent an early oncogenic event contributing to cell proliferation and growth. Although the presence of a kinase fusion does not seem to correlate with the biologic potential of a given lesion, documentation of a kinase fusion will likely be important, particularly in the case of spitzoid melanoma, as numerous specific kinase receptor inhibitors have shown promise as therapeutic agents in a subset of cases with kinase fusions. Interrogation of non-spitzoid melanomas for similar kinase fusions as a potential driving oncogenic mechanism has revealed some similarities and some differences. This review will focus on the kinase fusions described to date in spitzoid neoplasms and how subsequent studies have informed current melanoma research.
Collapse
|
110
|
Blum A, Tanaka M, Kraemer-Schultheiss KS, Bauer J. [Congenital nevus, atypical spitz nevus or spitzoid melanoma?]. Hautarzt 2017; 68:340-341. [PMID: 28102445 DOI: 10.1007/s00105-017-3932-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- A Blum
- Hautarztpraxis Konstanz, Augustinerplatz 7, 78462, Konstanz, Deutschland.
| | - M Tanaka
- Tokyo Women's Medical University Medical Center East, Tokyo, Japan
| | | | - J Bauer
- Universitäts-Hautklinik Tübingen, Tübingen, Deutschland
| |
Collapse
|
111
|
Dumitru C, Constantin C, Popp C, Cioplea M, Zurac S, Vassu T, Neagu M. Innovative array-based assay for omics pattern in melanoma. J Immunoassay Immunochem 2017; 38:343-354. [PMID: 28613106 DOI: 10.1080/15321819.2017.1340898] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Cutaneous melanoma remains a major health issue and still an important challenge for research. Thus, omics complex evaluation can provide a more specific molecular classification for this heterogeneous disease. Complex omics analysis based on genomic and proteomic microarrays can identify disease markers that prognosticate disease evolution or can monitor therapies efficacy. Among the technologies that gained momentum in the last years, array-based comparative genomic hybridization offered the possibility to analyze chromosomal numerical aberrations within cutaneous melanomas providing important support for molecular classification of melanoma tumors. This technology can identify new chromosomal alterations and discover new deregulated melanoma genes that can be further used as therapy targets. Integrating genetic profiling with clinical and pathological parameters would lead to seminal improvements in diagnosis, prognosis, and therapy.
Collapse
Affiliation(s)
- Carmen Dumitru
- a Department of Pathology , "Colentina" Clinical Hospital , Bucharest , Romania
| | - Carolina Constantin
- a Department of Pathology , "Colentina" Clinical Hospital , Bucharest , Romania
- b Department of Immunology , "Victor Babes" National Institute of Pathology , Bucharest , Romania
| | - Cristiana Popp
- a Department of Pathology , "Colentina" Clinical Hospital , Bucharest , Romania
- c Department of Physiology "Carol Davila" University of Medicine and Pharmacy , Bucharest , Romania
| | - Mirela Cioplea
- a Department of Pathology , "Colentina" Clinical Hospital , Bucharest , Romania
- c Department of Physiology "Carol Davila" University of Medicine and Pharmacy , Bucharest , Romania
| | - Sabina Zurac
- a Department of Pathology , "Colentina" Clinical Hospital , Bucharest , Romania
- c Department of Physiology "Carol Davila" University of Medicine and Pharmacy , Bucharest , Romania
| | - Tatiana Vassu
- d Faculty of Biology , University of Bucharest , Bucharest , Romania
| | - Monica Neagu
- a Department of Pathology , "Colentina" Clinical Hospital , Bucharest , Romania
- b Department of Immunology , "Victor Babes" National Institute of Pathology , Bucharest , Romania
- d Faculty of Biology , University of Bucharest , Bucharest , Romania
| |
Collapse
|
112
|
de la Fouchardière A. [Cutaneous melanocytic tumors. Case 1]. Ann Pathol 2016; 36:317-321. [PMID: 27641817 DOI: 10.1016/j.annpat.2016.08.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2016] [Accepted: 08/09/2016] [Indexed: 11/18/2022]
|
113
|
Bitterman A. Molecular testing to differentiate melanoma from benign nevi: The gold standard limitation. J Am Acad Dermatol 2016; 75:849-850. [PMID: 27646748 DOI: 10.1016/j.jaad.2016.06.038] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2016] [Revised: 06/16/2016] [Accepted: 06/22/2016] [Indexed: 11/25/2022]
Affiliation(s)
- Avi Bitterman
- Jefferson Medical College (Sidney Kimmel Medical College), Philadelphia, Pennsylvania; Department of Medicine, Jersey Shore University Medical Center, Neptune City, New Jersey.
| |
Collapse
|
114
|
Advances in melanoma: revolutionary progress delivering improved patient management and outcomes. Pathology 2016; 48:105-7. [DOI: 10.1016/j.pathol.2015.12.011] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|